Medicine used to treat Sickle Cell Anemia
Drug Name | Manufacturer | Mechanism of Action | Used for Child or Adult |
---|---|---|---|
Hydroxyurea (Xromi) | Bristol Myers Squibb, Cipla, etc | Increases HbF levels, decreases neutrophils, increases water content of RBCs, changes RBC adherence | Child (6 months – <2 years) |
Vitamin E | Matrix Life Science, etc | Acts as an antioxidant, improves bioavailability | Not specified |
Droxia | Cipla, Sarabhai Chemicals Ltd | Reduces pain episodes and need for blood transfusions in sickle cell anemia | Adult |
Glutamine (Endari) | Emmaus Life Sciences | Increases glutamine in blood, reduces oxidative damage in sickle RBCs | Adult and pediatric (5+ years) |
Siklos | Not specified | Not specified | Not specified |
Endari | Emmaus Life Sciences | Increases glutamine in blood, reduces oxidative damage in sickle RBCs | Adult and pediatric (5+ years) |
Adakveo | Novartis | Reduces frequency of vaso-occlusive crises | Adult (16+ years) |
Crizanlizumab | Novartis | Reduces frequency of vaso-occlusive crises | Adult (16+ years) |
This table provides a clear overview of the drugs used in sickle cell disease, including their manufacturers, mechanisms of action, and their suitability for children or adults.